Aden et al. (128) suggest that metabolic network reconstruction and assessment of metabolic profiles of fecal samples could be used to identify patients with IBD likely to achieve clinical remission following anti-TNF therapy. This evidence concerns the gene TNF and irritable bowel syndrome.